Status:

COMPLETED

Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa

Lead Sponsor:

Bayer

Conditions:

Acne Vulgaris

Eligibility:

FEMALE

16-45 years

Phase:

PHASE3

Brief Summary

The purpose of the study is to determine safety and efficacy of an oral contraceptive in treating acne papulopustulosa.

Detailed Description

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Eligibility Criteria

Inclusion

  • Patients with mild to moderate facial papulopustular acne

Exclusion

  • Contraindication against use of hormonal contraceptives

Key Trial Info

Start Date :

March 10 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 21 2005

Estimated Enrollment :

1326 Patients enrolled

Trial Details

Trial ID

NCT00280657

Start Date

March 10 2004

End Date

May 21 2005

Last Update

June 6 2023

Active Locations (62)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 16 (62 locations)

1

Chomutov, Czechia, 43012

2

Čáslav, Czechia, 28601

3

Kutná Hora, Czechia, 28401

4

Louny, Czechia, 44001